S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
"How war impacts the stock market" (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
"How war impacts the stock market" (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
"How war impacts the stock market" (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
"How war impacts the stock market" (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News

$7.66
+0.19 (+2.54%)
(As of 06/6/2023 ET)
Compare
Today's Range
$7.37
$7.73
50-Day Range
$6.41
$9.58
52-Week Range
$3.46
$9.82
Volume
465,760 shs
Average Volume
568,062 shs
Market Capitalization
$387.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.29

Marinus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
243.2% Upside
$26.29 Price Target
Short Interest
Healthy
3.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.80) to ($2.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

259th out of 981 stocks

Pharmaceutical Preparations Industry

118th out of 462 stocks


MRNS stock logo

About Marinus Pharmaceuticals (NASDAQ:MRNS) Stock

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
JMP Securities Keeps Their Buy Rating on Marinus (MRNS)
See More Headlines

MRNS Price History

MRNS Company Calendar

Last Earnings
11/09/2021
Today
6/06/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNS
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.29
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+243.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-19,820,000.00
Net Margins
-169.99%
Pretax Margin
-146.71%

Debt

Sales & Book Value

Annual Sales
$25.48 million
Book Value
$2.26 per share

Miscellaneous

Free Float
48,091,000
Market Cap
$387.21 million
Optionable
Optionable
Beta
1.15

Key Executives

  • Scott N. Braunstein
    Chairman, President & Chief Executive Officer
  • Steven E. Pfanstiel
    Chief Operating Officer, CFO & Treasurer
  • Joseph Hulihan
    Chief Medical Officer
  • Michael S. Saporito
    Vice President-Research
  • Martha E. Manning
    Secretary, Senior Vice President & General Counsel













MRNS Stock - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price forecast for 2023?

6 brokerages have issued 1 year price objectives for Marinus Pharmaceuticals' shares. Their MRNS share price forecasts range from $18.00 to $42.00. On average, they anticipate the company's stock price to reach $26.29 in the next year. This suggests a possible upside of 243.2% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2023?

Marinus Pharmaceuticals' stock was trading at $3.98 at the beginning of 2023. Since then, MRNS stock has increased by 92.5% and is now trading at $7.66.
View the best growth stocks for 2023 here
.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,830,000 shares, an increase of 19.6% from the April 30th total of 1,530,000 shares. Based on an average trading volume of 630,600 shares, the short-interest ratio is currently 2.9 days.
View Marinus Pharmaceuticals' Short Interest
.

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our MRNS earnings forecast
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.23. The biopharmaceutical company had revenue of $10.11 million for the quarter, compared to analyst estimates of $2.32 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 179.11% and a negative net margin of 169.99%. During the same quarter in the prior year, the business earned ($0.51) EPS.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), iShares Biotechnology ETF (IBB),

When did Marinus Pharmaceuticals' stock split?

Marinus Pharmaceuticals's stock reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Suvretta Capital Management LLC (9.56%), AIGH Capital Management LLC (2.64%), GMT Capital Corp (2.38%), BlackRock Inc. (2.27%), Franklin Resources Inc. (2.07%) and Assenagon Asset Management S.A. (1.37%).
View institutional ownership trends
.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $7.66.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $387.21 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

The company employs 113 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565.

This page (NASDAQ:MRNS) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -